Similarly, in a BLCA cohort receiving immunotherapy, we also found that patients with high DDR scores had higher immunogenicity than patients with low DDR scores, and the patients with high DDR scores showed increased TMB and NAL levels (Figure 5I, all P < 0.05). This evidence concerns the gene NPL and bladder transitional cell carcinoma.